AC Immune SA (ACIU)
ACIU Price and Sentiment
ACIU Latest news
AC Immune Announces Late-Breaker Presentation by Genentech at CTAD on Phase 2 Lauriet Study of Semorinemab in Mild-to-Moderate Alzheimer's Disease2021-11-10 11:20
Analysis of the broader mITT population is consistent with the previously reported success in meeting one of the two co-primary endpoints (ADAS-Cog11) with statistically significant reduction in the rate of cognitive decline vs. placebo
AC Immune (ACIU) delivered earnings and revenue surprises of 17.24% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
The stock price of AC Immune SA (NASDAQ: ACIU) increased over 9% pre-market today. This is why it happened.
Announced the first positive cognitive results for a Tau-targeting monoclonal antibody in mild-to-moderate Alzheimer's disease
AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AC Immune Extends Research Collaboration with University of Pennsylvania Focusing on the Pathogenic Protein TDP-43, a Major Driver of Neurodegenerative Diseases2021-11-04 06:00
LAUSANNE, Switzerland, Nov. 04, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced it is extending its research partnership with leading scientists at the Center for Neurodegenerative Disease Research at the Perelman School of Medicine at the University of Pennsylvania (Penn). The partnership is focused on studying the pathological mechanism of transactive response DNA binding protein 43 kDa (TDP-43) misfolding, aggregation and cell-to-cell transmission.
New Data on AC Immune's Abeta and pTau Clinical Programs in Alzheimer's Disease To Be Presented at CTAD 20212021-11-02 07:30
LAUSANNE, Switzerland, Nov. 02, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announces that new data on its investigational Alzheimer's disease (AD) candidates semorinemab, ACI-35.030 and ACI-24 will be featured in the scientific program of the Clinical Trials on Alzheimer's Disease (C-TAD) Conference, taking place virtually and in person in Boston, on November 9-12, 2021.
Dr. Shaw is a pharmaceutical industry expert who has been involved in advancing more than 15 therapeutic products from first-in-human studies through commercialization
LAUSANNE, Switzerland, Oct. 25, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company management will participate in a fireside chat and one-on-one investor meetings during the virtual portion of the Jefferies London Healthcare Conference, taking place November 18-19, 2021.
The ardor for shares of AC Immune SA ( ACIU , Financial) has cooled considerably since the company's Aug. 31 announcement of somewhat promising study results for its Alzheimer's drug. The Swiss biotech's stock shot up to a 52-week high of $12.61, but has since been halved as investors questioned how meaningful the trial results were.